Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s What Happened

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares were up 21.1% on Friday . The stock traded as high as $26.15 and last traded at $28.1640. Approximately 688,138 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 1,991,956 shares. The stock had previously closed at $23.25.

Analyst Ratings Changes

ELVN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Stock Up 13.2%

The firm’s 50 day simple moving average is $19.02 and its 200-day simple moving average is $19.93. The company has a market capitalization of $1.56 billion, a PE ratio of -14.32 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $16.84, for a total value of $84,200.00. Following the completion of the sale, the insider owned 897,688 shares in the company, valued at approximately $15,117,065.92. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $21.82, for a total value of $272,750.00. Following the sale, the chief executive officer owned 890,392 shares in the company, valued at approximately $19,428,353.44. The trade was a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 68,330 shares of company stock valued at $1,434,762 over the last quarter. Company insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Quantbot Technologies LP increased its holdings in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $96,000. Tower Research Capital LLC TRC boosted its stake in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its position in shares of Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after buying an additional 2,500 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.